J&J Says Duragesic Pediatric Exclusivity Is Unrelated To 30-Month Stay
Executive Summary
Allowing Mylan to launch generic Duragesic prior to the expiration of its pediatric exclusivity violates congressional intent, Johnson & Johnson says
You may also be interested in...
J&J Duragesic Pediatric Exclusivity Blocks Mylan Generic Until January
Mylan's generic fentanyl transdermal patch is blocked from launching before January 2005 by J&J/Alza's six-month pediatric exclusivity on Duragesic, FDA said
J&J Duragesic Pediatric Exclusivity Blocks Mylan Generic Until January
Mylan's generic fentanyl transdermal patch is blocked from launching before January 2005 by J&J/Alza's six-month pediatric exclusivity on Duragesic, FDA said
Mylan Loses Duragesic Case; Generic Launch Timing Dispute Moves To FDA
The launch timing for the first generic version of Johnson & Johnson/Alza's Duragesic fentanyl patch will depend on FDA's decision about a six-month pediatric exclusivity extension for the product